Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain

[1]  R. Collins,et al.  Social determinants of ethnic disparities in SARS-CoV-2 infection: UK Biobank SARS-CoV-2 Serology Study , 2023, Journal of Epidemiology & Community Health.

[2]  P. Klenerman,et al.  SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) , 2021, The Lancet.

[3]  G. Wogan,et al.  Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset , 2021, Proceedings of the National Academy of Sciences.

[4]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[5]  G. Rodger,et al.  The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[6]  R. Tibshirani,et al.  Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome , 2020, Science Immunology.

[7]  Samuel M. Brown,et al.  Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[8]  M. Hernán,et al.  Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study , 2020, BMJ.

[9]  D. Stuart,et al.  Antibodies to SARS-CoV-2 are associated with protection against reinfection , 2020, medRxiv.

[10]  Z. Livneh,et al.  Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation , 2020, EClinicalMedicine.

[11]  G. Screaton,et al.  The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers , 2020, medRxiv.

[12]  J. Sevinsky,et al.  Genomic evidence for reinfection with SARS-CoV-2: a case study , 2020, The Lancet Infectious Diseases.

[13]  P. Tambyah,et al.  Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays , 2020, Pathology.

[14]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[15]  A. Gylfason,et al.  Humoral Immune Response to SARS-CoV-2 in Iceland , 2020, The New England journal of medicine.

[16]  K. To,et al.  COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Kira L. Newman,et al.  Distinct Early Serological Signatures Track with SARS-CoV-2 Survival , 2020, Immunity.

[18]  Otto O. Yang,et al.  Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19 , 2020, The New England journal of medicine.

[19]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[20]  Quanxin Long,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[21]  C. Rice,et al.  Convergent antibody responses to SARS-CoV-2 in convalescent individuals , 2020, Nature.

[22]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[23]  Daniel S. Chertow,et al.  Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019 , 2020, The Journal of infectious diseases.

[24]  Amjad D. Al-Nasser,et al.  SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far , 2020, Pathogens.

[25]  M. McHugh.  Interrater reliability: the kappa statistic , 2012, Biochemia medica.

[26]  James E. Crowe,et al.  Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors , 2008, Nature.

[27]  G. M. Allan,et al.  Kappa statistic , 2005, Canadian Medical Association Journal.

[28]  Luis Villarreal,et al.  Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination 1 , 2003, The Journal of Immunology.

[29]  THE WORLD HEALTH ORGANIZATION , 1954 .